Please enable Javascript
Michael B. Atkins, MD
Michael B. Atkins, MD, Lombardi Comprehensive Cancer Center
Articles by Michael B. Atkins, MD
Beyond LAG-3: Promising Immuno-Oncology Targets in Kidney Cancer
Michael B. Atkins, MD
Advanced Renal Cell Carcinoma
|
April 11, 2024
Drs. Atkins and Beckermann weigh the potential of targeting Tregs in RCC treatment, particularly in relation to PD-1 therapy.
View More
The Potential Synergistic Power of LAG-3 and PD-1 in Kidney Cancer
Michael B. Atkins, MD
Advanced Renal Cell Carcinoma
|
April 11, 2024
Drs. Atkins and Beckermann consider biomarkers for patient selection for LAG-3 inhibition and increasing cure rates in RCC.
View More
Redefining Immune Strategies: LAG-3 With PD-1 in Kidney Cancer
Michael B. Atkins, MD
Advanced Renal Cell Carcinoma
|
April 11, 2024
Drs. Atkins and Beckermann discuss LAG-3 as a novel checkpoint inhibitor combined with anti-PD-1 for kidney cancer.cC
View More
Dr. Michael Atkins on Potential RCC Debate at Uromigos: Live & Unplugged
Michael B. Atkins, MD
Uromigos Live 2023
|
November 6, 2023
Dr. Michael Atkins discusses long-term results of IO/TKI combinations for metastatic RCC and how they may influence debate.
View More
Adjuvant RCC Treatment Considerations and Final Thoughts on RCC Therapy
Brian Rini, MD, FASCO
Roundtable
|
July 5, 2023
The panel provides their concluding thoughts on the frontline and refractory RCC treatment landscape.
View More
Panel Reacts to CONTACT-03 Data Presented at ASCO 2023, Thoughts on Adjuvant Therapy
Brian Rini, MD, FASCO
Roundtable
|
July 5, 2023
The panel discusses treatment options in the refractory RCC setting.
View More
Panelists Share What Is Most Exciting in Frontline Kidney Cancer
Brian Rini, MD, FASCO
Roundtable
|
July 5, 2023
The panel discusses what is most exciting to them in the frontline RCC field.
View More
Patient Selection for IO/IO Versus IO/TKI in the Frontline Setting
Brian Rini, MD, FASCO
Roundtable
|
July 5, 2023
The panel discusses toxicity management and use of precision medicine.
View More
Panelists Share How CLEAR and KEYNOTE-426 Data Presented at ASCO 2023 Impact Treatment Decisions
Brian Rini, MD, FASCO
Roundtable
|
July 5, 2023
The panelists debate the use of IO/IO versus IO/TKI regimens for frontline RCC therapy.
View More
ASCO 2023 Data in Frontline RCC: CLEAR and KEYNOTE-426 Trial Updates
Brian Rini, MD, FASCO
Roundtable
|
July 5, 2023
Dr. Rini describes the CLEAR and KEYNOTE-426 studies presented at ASCO 2023.
View More
Panelists Discuss Their Algorithm for Treating Frontline RCC
Brian Rini, MD, FASCO
Roundtable
|
July 5, 2023
The panel discusses the approach to frontline treatment selection for patients with RCC.
View More
HCRN GU16-260: Nivolumab, Salvage Nivo/Ipi in Advanced Clear Cell RCC
Michael B. Atkins, MD
ASCO GU Symposium 2023
|
March 10, 2023
Michael Atkins, MD, discusses TFS outcomes from the phase II study and argues for immunotherapy in favorable-risk patients.
View More